SRPT Stock Overview
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
Sarepta Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$75.22|
|52 Week High||US$101.24|
|52 Week Low||US$61.28|
|1 Month Change||9.83%|
|3 Month Change||-2.65%|
|1 Year Change||-6.44%|
|3 Year Change||-50.50%|
|5 Year Change||123.14%|
|Change since IPO||92.87%|
Recent News & Updates
Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|SRPT||US Biotechs||US Market|
Return vs Industry: SRPT exceeded the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: SRPT exceeded the US Market which returned -20.5% over the past year.
|SRPT Average Weekly Movement||6.6%|
|Biotechs Industry Average Movement||12.9%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||16.5%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: SRPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SRPT's weekly volatility (7%) has been stable over the past year.
About the Company
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
Sarepta Therapeutics Fundamentals Summary
|SRPT fundamental statistics|
Is SRPT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SRPT income statement (TTM)|
|Cost of Revenue||US$875.93m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.07|
|Net Profit Margin||-46.56%|
How did SRPT perform over the long term?See historical performance and comparison
Is SRPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SRPT?
Other financial metrics that can be useful for relative valuation.
|What is SRPT's n/a Ratio?|
Price to Sales Ratio vs Peers
How does SRPT's PS Ratio compare to its peers?
|SRPT PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: SRPT is good value based on its Price-To-Sales Ratio (8.6x) compared to the peer average (21.2x).
Price to Earnings Ratio vs Industry
How does SRPT's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Sales vs Industry: SRPT is good value based on its Price-To-Sales Ratio (8.6x) compared to the US Biotechs industry average (13.8x)
Price to Sales Ratio vs Fair Ratio
What is SRPT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||8.6x|
|Fair PS Ratio||4.5x|
Price-To-Sales vs Fair Ratio: SRPT is expensive based on its Price-To-Sales Ratio (8.6x) compared to the estimated Fair Price-To-Sales Ratio (4.5x).
Share Price vs Fair Value
What is the Fair Price of SRPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SRPT ($75.22) is trading below our estimate of fair value ($695.51)
Significantly Below Fair Value: SRPT is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SRPT's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Sarepta Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: SRPT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SRPT is expected to become profitable in the next 3 years.
Revenue vs Market: SRPT's revenue (32.8% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: SRPT's revenue (32.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SRPT is forecast to be unprofitable in 3 years.
Discover growth companies
How has Sarepta Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRPT is currently unprofitable.
Growing Profit Margin: SRPT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SRPT is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.
Accelerating Growth: Unable to compare SRPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: SRPT has a negative Return on Equity (-41.61%), as it is currently unprofitable.
Discover strong past performing companies
How is Sarepta Therapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SRPT's short term assets ($2.5B) exceed its short term liabilities ($455.0M).
Long Term Liabilities: SRPT's short term assets ($2.5B) exceed its long term liabilities ($1.7B).
Debt to Equity History and Analysis
Debt Level: SRPT has more cash than its total debt.
Reducing Debt: SRPT's debt to equity ratio has increased from 3.2% to 128.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SRPT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SRPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Sarepta Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SRPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SRPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SRPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRPT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SRPT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug Ingram (58 yo)
Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as an Independent Director of Rela...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD1.55M) is below average for companies of similar size in the US market ($USD8.47M).
Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.
Experienced Management: SRPT's management team is considered experienced (2 years average tenure).
Experienced Board: SRPT's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.7%.
Sarepta Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Sarepta Therapeutics, Inc.
- Ticker: SRPT
- Exchange: NasdaqGS
- Founded: 1980
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$6.284b
- Shares outstanding: 87.50m
- Website: https://www.sarepta.com
Number of Employees
- Sarepta Therapeutics, Inc.
- 215 First Street
- Suite 415
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.